The following is a summary of "Sex differences in outcomes in patients with acute myocardial infarction," published in the ...

A potential strategy introduces an entirely new type of therapy capable of addressing previously ‘undruggable’ targets within ...

For patients with myocardial infarction (MI), early oral combination lipid-lowering therapy (LLT) is beneficial, according to ...

Inflammation is likely a key player in atherosclerosis and related cardiovascular events, but questions remain about its role ...

Indian multinational pharmaceutical company, Zydus Lifesciences Limited, has received final approval from the United States ...

In a recent study, one-year MACE incidences were 1.79, 2.58, and 4.03 per 100 patient-years for early, late, and no ezetimibe added to statins. (HealthDay News) — For patients with myocardial ...

In one of the largest studies of early cardiogenic shock (CS) patients, where blood flow is still functioning to vital organs ...

The SOUL trial showed that oral semaglutide was safe in patients with type 2 diabetes and atherosclerotic cardiovascular ...

Febuxostat does not appear to increase the risk for major adverse cardiovascular events when compared with no urate-lowering ...